Abstract
The antiarrhythmic effects and pharmacodynamics of tobanum were evaluated in 28 patients wist paroxysms of reciprocal atrioventricular tachycardia, by using transesophageal cardiac pacing. The agent given in a single dose of 10 mg produced antiarrhythmic effects in 70% patients with paroxysms of atrioventricular nodal tachycardia and in 40% with atrioventricular tachycardia in the presence of the Wolff--Parkinson-White syndrome. After administration of the drug, its antiarrhythmic effect occurred on an average 1.5 h and retained for 27 h.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
MeSH terms
-
Adolescent
-
Adrenergic beta-Antagonists / therapeutic use*
-
Adult
-
Aged
-
Anti-Arrhythmia Agents / therapeutic use*
-
Atrioventricular Node / drug effects*
-
Atrioventricular Node / physiopathology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Placebos
-
Propanolamines / therapeutic use*
-
Tachycardia, Atrioventricular Nodal Reentry / drug therapy*
-
Tachycardia, Atrioventricular Nodal Reentry / physiopathology
-
Tachycardia, Paroxysmal / drug therapy*
-
Tachycardia, Paroxysmal / physiopathology
Substances
-
Adrenergic beta-Antagonists
-
Anti-Arrhythmia Agents
-
Placebos
-
Propanolamines
-
tobanum